Exhibit 10.1
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to
the confidentiality request. Omissions are designated as [***].
COLLABORATION AGREEMENT
This Agreement is entered into as of June18, 2004 by and between:
SEATTLE GENETICS, INC. , a Delaware corporation, having its principal place of business at 21823 30th Drive S.E.,
Bothell, Washington 98021
(hereinafter referred to as “ SGI ”)
and :
CURAGEN CORPORATION , a Delaware corporation, having its principal place of business at 555 Long Wharf Avenue,
New Haven, CT 06511
(hereinafter referred to as “ Licensee ”).
WITNESSETH
WHEREAS, SGI owns or controls intellectual property rights relating to certain technology useful for linking certain
proprietary cytotoxins to other molecules such as antibodies capable of directing such cytotoxins to specific tissues and/or
cells;
WHEREAS, Licensee is currently conducting research and development programs to discover antigens that may have
activity in certain disease-related pathways, and to develop antibodies that bind to those antigens;
WHEREAS, the Parties have created ADCs (as such term is defined below) to, and conducted initial characterization work
regarding, the First Exclusive Antigen (as such term is defined below) pursuant to the terms and subject to the conditions of the
Initial Agreements (as such term is defined below);
WHEREAS, Licensee wishes to obtain an exclusive worldwide license under certain of SGI’s patent rights and know-how
related to SGI’s proprietary cytotoxin and linker technology to the First Exclusive Antigen for use in conjunction with
Licensee’s antibodies on the terms set forth below and Licensee wishes to acquire from SGI an exclusive option to obtain an
exclusive worldwide license under SGI’s patent rights and know-how related to SGI’s proprietary cytotoxin and linker
technology to a Second Exclusive Antigen for use in con